MedPath

EYLEA HD

These highlights do not include all the information needed to use EYLEA HD safely and effectively. See full prescribing information for EYLEA HD. EYLEA HD (aflibercept) injection, for intravitreal use Initial U.S. Approval: 2011

Approved
Approval ID

86d8848b-111b-4da9-8957-7cccef1b8f66

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Dec 14, 2023

Manufacturers
FDA

Regeneron Pharmaceuticals, Inc

DUNS: 194873139

Products 2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

aflibercept

PRODUCT DETAILS

NDC Product Code61755-050
Application NumberBLA761355
Marketing CategoryC73585
Route of AdministrationINTRAVITREAL
Effective DateDecember 14, 2023
Generic Nameaflibercept

INGREDIENTS (6)

afliberceptActive
Quantity: 8 mg in 0.07 mL
Code: 15C2VL427D
Classification: ACTIB
polysorbate 20Inactive
Code: 7T1F30V5YH
Classification: IACT
sucroseInactive
Code: C151H8M554
Classification: IACT
arginine hydrochlorideInactive
Code: F7LTH1E20Y
Classification: IACT
histidineInactive
Code: 4QD397987E
Classification: IACT
HISTIDINE MONOHYDROCHLORIDE MONOHYDRATEInactive
Code: X573657P6P
Classification: IACT

aflibercept

PRODUCT DETAILS

NDC Product Code61755-051
Application NumberBLA761355
Marketing CategoryC73585
Route of AdministrationINTRAVITREAL
Effective DateDecember 14, 2023
Generic Nameaflibercept

INGREDIENTS (6)

polysorbate 20Inactive
Code: 7T1F30V5YH
Classification: IACT
arginine hydrochlorideInactive
Code: F7LTH1E20Y
Classification: IACT
histidineInactive
Code: 4QD397987E
Classification: IACT
HISTIDINE MONOHYDROCHLORIDE MONOHYDRATEInactive
Code: X573657P6P
Classification: IACT
afliberceptActive
Quantity: 8 mg in 0.07 mL
Code: 15C2VL427D
Classification: ACTIB
sucroseInactive
Code: C151H8M554
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

EYLEA HD - FDA Drug Approval Details